Ciprofolxacin Injectable (iv) Generics - Manufacturers & Suppliers
Cipro(US & EU)
| Product/Composition:- | Ciprofolxacin Injectable (IV) |
|---|---|
| Strength:- | 200 mg/100 mL, 400 mg/200 mL |
| Form:- | Injectable (IV) |
| Reference Brands:- | Cipro(US & EU) |
| MOQ | As per the manufacturer batch size |
| Get Quote Send Enquiry on WhatsApp | |
Ciprofloxacin IV inhibits bacterial DNA gyrase and topoisomerase IV, blocking DNA replication and leading to bacterial cell death. It provides rapid, broad-spectrum activity against severe infections such as sepsis and pneumonia. Benefits include high tissue penetration, quick onset, and effective treatment of serious bacterial infections in hospital settings.
Ciprofloxacin IV is approved in the EU and US for severe bacterial infections, including sepsis, pneumonia, and complicated urinary tract infections. In the EU, brands like Cipro are regulated by EMA, supported by dossiers demonstrating safety, efficacy, and manufacturing standards. In the US, FDA approval relies on extensive clinical data; generic formulations are available. Both regions require detailed dossiers, including clinical trial results, manufacturing practices, and pharmacovigilance plans for approval and ongoing safety monitoring. For expert assistance with regulatory dossiers, compliance, and registration, visit PharmaTradz. We support seamless market access for ciprofloxacin IV, ensuring adherence to European and US standards for safe, effective treatment of serious bacterial infections.